
## LluÃ-s RamiÃ<sup>3</sup>-TorrentÃ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5745362/publications.pdf

Version: 2024-02-01



<u>Ιιμῶς Ραμιῶβ-Τορρεντῶ</u>

#	Article	IF	CITATIONS
1	Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans. Cell Host and Microbe, 2022, 30, 340-356.e8.	5.1	50
2	The effect of external stimulation on functional networks in the aging healthy human brain. Cerebral Cortex, 2022, 33, 235-245.	1.6	8
3	Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses. Journal of Personalized Medicine, 2022, 12, 6.	1.1	8
4	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	1.4	11
5	Microbiota alterations in proline metabolism impact depression. Cell Metabolism, 2022, 34, 681-701.e10.	7.2	77
6	Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. Cells, 2022, 11, 2058.	1.8	35
7	Whole-Brain Dynamics in Aging: Disruptions in Functional Connectivity and the Role of the Rich Club. Cerebral Cortex, 2021, 31, 2466-2481.	1.6	29
8	Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis. Brain and Behavior, 2021, 11, e02044.	1.0	2
9	A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2240-2253.	1.4	28
10	Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study). Multiple Sclerosis and Related Disorders, 2021, 50, 102860.	0.9	10
11	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	2.2	13
12	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	4.9	89
13	Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways. Gut, 2021, 70, 2283-2296.	6.1	31
14	Obesity Impairs Short-Term and Working Memory through Gut Microbial Metabolism of Aromatic Amino Acids. Cell Metabolism, 2020, 32, 548-560.e7.	7.2	88
15	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	4.9	64
16	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Epigenomics, 2020, 12, 2065-2076.	1.0	12
17	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. Mechanisms of Ageing and Development, 2020, 189, 111257.	2.2	18
18	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	1.1	1

LluÃs RamiÃ<sup>3</sup>-TorrentÃ

#	Article	IF	CITATIONS
19	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. Journal of Clinical Medicine, 2020, 9, 625.	1.0	5
20	Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 581.	1.1	70
21	Perception of stigma in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985271.	0.5	7
22	Glycated Hemoglobin, but not Insulin Sensitivity, is Associated with Memory in Subjects with Obesity. Obesity, 2019, 27, 932-942.	1.5	9
23	Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions. Journal of Neuroinflammation, 2019, 16, 220.	3.1	48
24	One-shot domain adaptation in multiple sclerosis lesion segmentation using convolutional neural networks. Neurolmage: Clinical, 2019, 21, 101638.	1.4	91
25	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	3.7	115
26	A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis. NeurologÃa (English Edition), 2018, 33, 327-337.	0.2	2
27	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. Journal of Neuroinflammation, 2018, 15, 265.	3.1	25
28	Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients. Neurological Sciences, 2018, 39, 1423-1430.	0.9	7
29	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	1.4	77
30	miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands. Multiple Sclerosis Journal, 2017, 23, 1716-1726.	1.4	58
31	Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. NeuroImage, 2017, 155, 159-168.	2.1	287
32	Evaluating the effect of multiple sclerosis lesions on automatic brain structure segmentation. NeuroImage: Clinical, 2017, 15, 228-238.	1.4	19
33	Automated tissue segmentation of MR brain images in the presence of white matter lesions. Medical Image Analysis, 2017, 35, 446-457.	7.0	55

Paraneoplastic Limbic Encephalitis in a Male with Squamous Cell Carcinoma of the Lung. Journal of

#	Article	IF	CITATIONS
37	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	2.8	48
38	A toolbox for multiple sclerosis lesion segmentation. Neuroradiology, 2015, 57, 1031-1043.	1.1	76
39	A new cognitive rehabilitation programme for patients with multiple sclerosis: the â€~MS-line! Project'. Multiple Sclerosis Journal, 2015, 21, 1344-1348.	1.4	3
40	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Multiple Sclerosis Journal, 2015, 21, 866-874.	1.4	241
41	BOOST: A supervised approach for multiple sclerosis lesion segmentation. Journal of Neuroscience Methods, 2014, 237, 108-117.	1.3	28
42	Clinical and Neuropathological Variability in Clinically Isolated Central Nervous System <scp>W</scp> hipple's Disease. Brain Pathology, 2014, 24, 230-238.	2.1	13
43	Intensity Based Methods for Brain MRI Longitudinal Registration. A Study on Multiple Sclerosis Patients. Neuroinformatics, 2014, 12, 365-379.	1.5	13
44	A Moroccan patient with Vogt–Koyanagi–Harada syndrome and bilateral Adie's pupils. Neurological Sciences, 2014, 35, 483-485.	0.9	2
45	A subtraction pipeline for automatic detection of new appearing multiple sclerosis lesions in longitudinal studies. Neuroradiology, 2014, 56, 363-374.	1.1	47
46	MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI. Computer Methods and Programs in Biomedicine, 2014, 113, 655-673.	2.6	32
47	Automatic multiple sclerosis lesion detection in brain MRI by FLAIR thresholding. Computer Methods and Programs in Biomedicine, 2014, 115, 147-161.	2.6	39
48	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	1.4	35
49	Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. European Journal of Paediatric Neurology, 2013, 17, 50-54.	0.7	45
50	Long-term clinical and radiological evolution in one case of Susac's syndrome. Neurological Sciences, 2012, 33, 1407-1410.	0.9	8
51	Automated detection of multiple sclerosis lesions in serial brain MRI. Neuroradiology, 2012, 54, 787-807.	1.1	76
52	Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Revista De Neurologia, 2012, 54, 677-91.	7.6	5
53	Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Revista De Neurologia, 2012, 54, 734-49.	7.6	5
54	Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain, 2008, 131, 2553-2563.	3.7	536

#	Article	IF	CITATIONS
55	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain, 2005, 128, 1454-1460.	3.7	135
56	Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. NeuroImage, 2004, 22, 353-359.	2.1	80